Customize your JAMA Network experience by selecting one or more topics from the list below.
Grigsby PW, Siegel BA, Baker S, Eichling JO. Radiation Exposure From Outpatient Radioactive Iodine (131I) Therapy for Thyroid Carcinoma. JAMA. 2000;283(17):2272–2274. doi:10.1001/jama.283.17.2272
Author Affiliations: Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Mo.
Context In May 1997, the US Nuclear Regulatory Commission (NRC) revised its
patient release regulations, allowing for outpatient administration of larger
activities of sodium iodide 131I than previously permitted.
Objective To measure the radiation exposure to household members from patients
receiving outpatient 131I therapy for thyroid carcinoma in accordance
with the new regulations.
Design Consecutive case series from October 1998 to June 1999.
Setting and Patients Thirty patients who received outpatient 131I therapy following
thyroidectomy for differentiated thyroid carcinoma were enrolled, along with
their 65 household members and 17 household pets.
Main Outcome Measure Radiation exposure to household members and 4 rooms in each home, as
monitored with dosimeters for 10 days following 131I administration.
Results The patients received 131I doses ranging from 2.8 to 5.6
GBq (mean, 4.3 GBq). The radiation dose to 65 household members ranged from
0.01 mSv to 1.09 mSv (mean, 0.24 mSv). The dose to 17 household pets ranged
from 0.02 mSv to 1.11 mSv (mean, 0.37 mSv). The mean dose to the 4 rooms ranged
from 0.17 mSv (kitchen) to 0.58 mSv (bedroom).
Conclusion In our study, 131I doses to household members of patients
receiving outpatient 131I therapy were well below the limit (5.0
mSv) mandated by current NRC regulations.
Create a personal account or sign in to: